Skip to main content
. 2023 Sep 14;22:248. doi: 10.1186/s12933-023-01979-1

Table 1.

Baseline characteristics. Data are expressed as mean +/- S.D. (for normal distribution), medians [25th -75th percentiles] or % of the population. Groups were compared with a student’s test or Kruskall-Wallis non-parametric test; qualitative data were compared using chi-squared or Fischer’s test

Controls
(n = 98)
Diabetics
(n = 101)
p-value
Age (years) 74.0 [62.2;79.0] 72.0 [65.0;78.0] 0.766
Gender (M/F) 72/26 77/24 0.653
BMI (kg/m2) 26.0 [23.0;28.0] 27.4 [25.0;30.0] 0.001
Active Smoking 28 (28.6%) 24 (23.8%) 0.440
Hypertension/antihypertensive drugs 80 (81.6%) 95 (94.1%) 0.007
Renal insufficiency 11 (11.2%) 12 (11.9%) 0.885
Diabetic treatment
No treatment or MHD 9 (10%) -
Biguanid 41 (45%) -
Sulfonylurea 12 (13%) -
Insulin 16 (17%) -
DDP-4 inhibitor 5 (5.4%) -
other 4 (4.4%)
Hypolipidemic treatment
Statin 53 (57%) 58 (63%)
Symptomatic lesions 38 (38.8%) 42 (41.6%) 0.686
Hyperechoic 29 (29.6%) 36 (35.6%) 0.632
Hypoechoic 18 (18.4%) 15 (14.9%) 0.505
NASCET 75.0 [65.0;85.0] 80.0[70.0;87.0] 0.005
Plaque Ulceration 13 (13.3%) 15 (14.9%) 0.748
Calcifications 0.104
1 14 (14.3%) 17 (16.8%)
2 75 (76.5%) 65 (64.4%)
3 9 (9.2%) 19 (18.8%)
HbA1c 5.74 [5.48;5.97] 6.79 [6.34;7.48] <0.001
Creatinine.µmol/L 74.9 [60.9;89.0] 71.8 [57.4;85.4] 0.305
Total cholesterol mmol/L 3.88 [3.24;4.44] 3.56 [2.83;4.21] 0.043
Triglycerides mmol/L 1.36 [0.94;1.82] 1.67 [1.14;2.36] 0.017
LDLc mmol/L 2.04 [1.49;2.66] 1.98 [1.46;2.54] 0.407
HDLc mmol/L 1.13 (0.34) 0.96 (0.28) <0.001
Hemoglobin (g/dl) (M) 12.8 [11.6;14.4] 13.2 [11.2;13.9] 0.540
Hemoglobin (g/dl) (F) 13.1 [11.7;14.4] 12.3 [10.6;15.2] 0.582
Erythrocytes (1012/L) (M) 4.28 [3.86;4.70] 4.27 [3.68;4.55] 0.582
Erythrocytes (1012/L) (F) 4.21 [3.79;4.78] 4.16 [3.60;4.63] 0.644
Platelets (109/L) 220 [181;253] 229 [188;284] 0.261
Neutrophils(109/L) 5.54 [4.52;7.51] 6.61 [4.83;8.72] 0.058
Lymphocytes (109/L) 1.76 [1.34;2.43] 1.69 [1.23;2.15] 0.482
Monocytes (109/L) 0.76 [0.59;0.94] 0.82 [0.64;0.99] 0.225